Filing Flows › Viemed Healthcare (VMD) › Q2 2025
Viemed Healthcare (VMD) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 6, 2025
Viemed Healthcare (VMD) reported revenue of $63.1M for the second quarter 2025 (Q2 2025), +15% from a year earlier and +7% from the quarter before. Operating margin was 8.1%, net earnings $3.2M (5.0% of revenue).
Viemed Healthcare, Q2 2025: revenue $63.1M (+15% year over year), operating margin 8.1%, net earnings $3.2M, operating cash flow $12.3M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $63.1M | +7% | +15% |
| Gross profit | $36.7M | +10% | +12% |
| Operating profit | $5.1M | +33% | +41% |
| Net earnings | $3.2M | +20% | +115% |
| Operating cash flow | $12.3M | +329% | +20% |
| Free cash flow | $4.1M | — | +231% |
What changed
Revenue was $63.1M in Q2 2025, up 15% year over year and up 7% from the previous quarter.
Gross margin was 58.3%, down 1.6 points from a year earlier. Operating profit was $5.1M, a 8.1% margin (up 1.5 points year over year). Of the extra revenue versus a year earlier, 18% reached operating profit, above the 7% margin then. Operating expenses grew 8% against revenue growth of 15%. The fastest-growing cost line was Research & development (+12%). Net earnings were $3.2M, up 115% year over year. The effective tax rate was 34.5%.
Operating cash flow was $12.3M (up 20% year over year), 377% of net income including minority interests. Non-cash charges added back $6.9M of depreciation and amortization and $2.3M of share-based compensation. Capital expenditures of $8.1M left free cash flow of $4.1M.
Questions
What was Viemed Healthcare's revenue in the second quarter 2025?
Viemed Healthcare (VMD) reported revenue of $63.1M for the second quarter 2025 (Q2 2025), +15% from a year earlier and +7% from the quarter before.
Was Viemed Healthcare profitable in the second quarter 2025?
Operating profit was $5.1M (8.1% of revenue) and net earnings $3.2M.
Source: Viemed Healthcare 10-Q on SEC EDGAR.